HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment

Reuters2025-06-05

HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment

HUTCHMED (China) Limited and Innovent Biologics, Inc. have jointly announced the acceptance of their New Drug Application (NDA) by the China National Medical Products Administration (NMPA). The application is for the combination of fruquintinib and sintilimab for the treatment of patients with advanced renal cell carcinoma who have not responded to prior treatment with a tyrosine kinase inhibitor. This NDA is backed by data from the FRUSICA-2 study, which demonstrated the efficacy and safety of the drug combination compared to monotherapy options. The announcement underscores both companies' commitment to advancing cancer therapies and enhancing treatment options for patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2541909742?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 07:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541909742","market":"us","top_or_hot":-1,"title":"HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Limited and Innovent Biologics, Inc. have jointly announced the acceptance of their New Drug Application (NDA) by the China National Medical Products Administration (NMPA). The application is for the combination of fruquintinib and sintilimab for the treatment of patients with advanced renal cell carcinoma who have not responded to prior treatment with a tyrosine kinase inhibitor. This NDA is backed by data from the FRUSICA-2 study, which demonstrated the efficacy and safety of the drug combination compared to monotherapy options. The announcement underscores both companies' commitment to advancing cancer therapies and enhancing treatment options for patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 07:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Limited and Innovent Biologics, Inc. have jointly announced the acceptance of their New Drug Application (NDA) by the China National Medical Products Administration (NMPA). The application is for the combination of fruquintinib and sintilimab for the treatment of patients with advanced renal cell carcinoma who have not responded to prior treatment with a tyrosine kinase inhibitor. This NDA is backed by data from the FRUSICA-2 study, which demonstrated the efficacy and safety of the drug combination compared to monotherapy options. The announcement underscores both companies' commitment to advancing cancer therapies and enhancing treatment options for patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1147","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL8P2WdD:1","article_id":"2541909742","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541909742","pubTimestamp":1749081005,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment. HUTCHMED  Limited and Innovent Biologics, Inc. have jointly announced the acceptance of their New Drug Application  by the China National Medical Products Administration . The application is for the combination of fruquintinib and sintilimab for the treatment of patients with advanced renal cell carcinoma who have not responded to prior treatment with a tyrosine kinase inhibitor. This NDA is backed by data from the FRUSICA-2 study, which demonstrated the efficacy and safety of the drug combination compared to monotherapy options. The announcement underscores both companies' commitment to advancing cancer therapies and enhancing treatment options for patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1147":"投资银行业与经纪业","BK1588":"回港中概股","BK1191":"制药","01911":"华兴资本控股","BK1587":"次新股","00013":"和黄医药"},"translate_title":"和黄医药和信达生物宣布呋喹替尼和信迪利单抗联合治疗晚期肾细胞癌在中国获得监管审查受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":0.9,"01911":0.9},"content_text":"HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment\n    \n\n        HUTCHMED (China) Limited and Innovent Biologics, Inc. have jointly announced the acceptance of their New Drug Application (NDA) by the China National Medical Products Administration (NMPA). The application is for the combination of fruquintinib and sintilimab for the treatment of patients with advanced renal cell carcinoma who have not responded to prior treatment with a tyrosine kinase inhibitor. This NDA is backed by data from the FRUSICA-2 study, which demonstrated the efficacy and safety of the drug combination compared to monotherapy options. The announcement underscores both companies' commitment to advancing cancer therapies and enhancing treatment options for patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2541909742","isCrawlerRequest":true}